Journal of Bone & Joint Surgery

Timothy A. Damron, MD; Jennifer Lisle, MD; Tina Craig, CRC

Michael Wade, MS; Walter Silbert, MD1; Hal Cohen, MD

Abstract
Background:  
Ultraporous β-tricalcium phosphate (TCP) synthetic graft material (Vitoss; Orthovita) persists for a year or longer in some cases. In this study, we prospectively examined healing of cavitary defects filled with TCP versus TCP and bone marrow aspirate (TCP/BM) with the hypothesis that bone-marrow aspirate speeds incorporation of bone graft substitute.